What’s going on with the pharma sector?

We are witnessing a “reset” across the industry, marked by an average decline of 9%. As with anything in the markets, this is no coincidence; rather, it’s a perfect storm of factors that has dragged down most of the sector.

The Patent Cliff

Several “blockbuster” patents that underpin major firms are nearing expiration. This loss of exclusivity is opening the door to cheaper generics, forcing established players to slash prices to remain competitive against emerging rivals. Lab-grown drugs like AbbVie’s Humira, which once catapulted their makers to the top, have lost the exclusivity that made them unique. A similar trend has hit Novo Nordisk, which was forced to cut prices on its weight-loss pills to fend off its primary competitor, Eli Lilly.

Regulatory Blows

Funding cuts to Medicare Advantage plans and pressure from the current administration to lower healthcare costs are squeezing margins. On top of this, “applied deflation” is forcing companies to mark down their products. Last but not least, the announcement of tariffs up to 100% on patented drugs manufactured outside the U.S. has sparked “logistical panic.” Companies now face a grim choice: invest billions to repatriate manufacturing to U.S. soil or accept significantly thinner margins. This has brought production to a grinding halt, with growth expected to plummet to 1.6% this year.

The impact on industry giants has been stark. Take UnitedHealth Group: for the first time since 1989, the company is projecting a drop in annual revenue.

A Two-Speed Sector

While other factors — such as interest rates, the rise of AI in R&D, and shifting drug demand — have played a role, the two issues mentioned above are the real drivers of this reset.

However, it isn’t all bad news. While these headwinds have battered large and mid-cap firms, small pharma companies are actually reaping the benefits. Large corporations are struggling with the 100% tariffs, leading to inefficient factory and lab closures. Mid-sized firms are arguably in the worst position: they lack the scale to lobby the government like Pfizer does, yet they aren’t small enough to be agile.

In contrast, small-cap players are thriving by focusing on specific niches that are proving profitable in the long run. Their goal isn’t to become the next “Big Pharma” sensation, but rather to scale up and become attractive acquisition targets for the giants. Finally, these smaller firms remain largely insulated from the heavy-handed bureaucracy currently weighing down the rest of the industry.

Andr€a